Panoramic Capital LLC Invests $9.11 Million in Halozyme Therapeutics, Inc. $HALO

Posted by George Bondi on Aug 27th, 2026

Panoramic Capital LLC acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 116,416 shares of the biopharmaceutical company’s stock, valued at approximately $9,112,000. Halozyme Therapeutics comprises 3.9% of Panoramic Capital LLC’s portfolio, making the stock its 8th biggest position.

Several other hedge funds and other institutional investors have also made changes to their positions in HALO. Empowered Funds LLC acquired a new position in Halozyme Therapeutics in the first quarter valued at approximately $755,000. Acadian Asset Management LLC purchased a new stake in shares of Halozyme Therapeutics during the 1st quarter worth approximately $195,000. Hsbc Holdings PLC boosted its holdings in shares of Halozyme Therapeutics by 117.1% in the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock valued at $522,000 after buying an additional 5,448 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 174 shares in the last quarter. Finally, Baird Financial Group Inc. boosted its holdings in shares of Halozyme Therapeutics by 6.2% in the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after buying an additional 650 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on HALO shares. Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $83.00 to $110.00 in a research note on Friday, August 7th. TD Cowen upped their price objective on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Wells Fargo & Company lifted their target price on Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Finally, Morgan Stanley reduced their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $91.20.

Check Out Our Latest Stock Analysis on HALO

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $107.06 on Thursday. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The firm has a market cap of $12.15 billion, a PE ratio of 31.96, a price-to-earnings-growth ratio of 0.44 and a beta of 0.85. The company’s 50 day simple moving average is $85.50 and its 200-day simple moving average is $74.39. Halozyme Therapeutics, Inc. has a 12-month low of $61.22 and a 12-month high of $109.66.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. The firm had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. Halozyme Therapeutics’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities analysts predict that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Mahesh Krishnan sold 7,304 shares of the company’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $75.00, for a total value of $547,800.00. Following the completion of the sale, the director directly owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. This represents a 33.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at $79,987,320.40. This trade represents a 2.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 64,103 shares of company stock worth $5,226,496. 2.50% of the stock is owned by company insiders.

Halozyme Therapeutics Company Profile

(Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.